Screener
Sarepta Therapeutics, Inc. SRPT Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
FAQ
- What is Sarepta Therapeutics, Inc.'s retained earnings?
- Sarepta Therapeutics, Inc. (SRPT) reported retained earnings of -$4.55B in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s retained earnings changed year-over-year?
- Sarepta Therapeutics, Inc.'s retained earnings decreased by 2.0% year-over-year, from -$4.46B to -$4.55B.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s retained earnings has grown at a 11.4% compound annual growth rate (CAGR), from -$2.85B to -$4.88B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Sarepta Therapeutics, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude